Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCH: Romosozumab vs Alendronate in Postmenopausal Osteoporosis
NCT01631214Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2012
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 42
01
Overview
A Phase 3 trial of romosozumab in postmenopausal osteoporosis, sponsored by Amgen. Started May 2012; status: completed.
02
Drugs
romosozumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT01631214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01631214.